Abstract
Pakistan's pharmaceutical sector, pivotal for GDP, employment, and poverty reduction, comprises 759 companies in dynamic growth. We employ Data Envelopment Analysis (DEA) to identify efficient firms in 2017-2018, showcasing DEA's superiority. Evaluating ten industry leaders, e.g., Merk, Abbott, and GSK, we assess variables like Assets, Liabilities, Sales, EPS, DPS, and ROE. High Noon excels in consistent efficiency, while others improved from 2017 inefficiencies. Sanofi, despite revenue, underutilized EPS, DPS, and ROE. The study emphasizes companies' global and national standings, offering revenue and resource optimization insights, and enhancing industry efficiency. Implementing suggestions aids firms and Pakistan's GDP, advancing the pharmaceutical sector. Valuable for international stakeholders to invest in Pakistan's pharmaceutical progress.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
